Companies › Advanced Accelerator Applications
1 active drug program in 28 registered trials: 17 Phase 2, 8 Phase 1, 2 Phase 3, 1 Phase 4; Gastroenterology, Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumors; Digestive System Neuroendocrine Tumor G1; Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) … | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04609592 | Lutetium Oxodotreotide Lu-177 | Phase 1 | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenterology | Nov 2026 |
| NCT06663072 | Lutetium Oxodotreotide Lu-177 | Phase 1 | Metastatic Pancreatic Neuroendocrine Tumor | Oncology | Nov 2026 |
| NCT05724108 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Metastatic Neuroendocrine Tumor | Oncology | Dec 2026 |
| NCT05687123 | Lutetium Oxodotreotide Lu-177 | Phase 1 | Metastatic Pancreatic Neuroendocrine Tumor | Oncology | Dec 2026 |
| NCT03971461 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Meningioma | Oncology | Jan 2027 |
| NCT04234568 | Lutetium Oxodotreotide Lu-177 | Phase 1 | Metastatic Digestive System Neuroendocrine Neoplasm | Oncology | Mar 2027 |
| NCT06326190 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Recurrent Meningioma | Oncology | Apr 2027 |
| NCT06016855 | Lutetium Oxodotreotide Lu-177 | Phase 4 | Digestive System Neuroendocrine Tumor G1 | Oncology | May 2027 |
| NCT05691465 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Oncology | Jun 2027 |
| NCT04082520 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Grade 1 Meningioma | Oncology | Sep 2027 |
| NCT07150546 | Lutetium Oxodotreotide Lu-177 | Phase 1 | Digestive System Neuroendocrine Tumor | Gastroenterology | Sep 2027 |
| NCT05247905 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Metastatic Pancreatic Neuroendocrine Tumor | Oncology | Oct 2027 |
| NCT03972488 | Lutetium Oxodotreotide Lu-177 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor | Gastroenterology | Oct 2027 |
| NCT05249114 | Lutetium Oxodotreotide Lu-177 | Phase 1 | Neuroendocrine Tumors | Oncology | Dec 2027 |
| NCT04529044 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | Oncology | Dec 2027 |
| NCT06126588 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Meningioma | Oncology | May 2028 |
| NCT05278208 | Lutetium Oxodotreotide Lu-177 | Phase 1 | High Grade Glioma | Oncology | Nov 2028 |
| NCT05583708 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Merkel Cell Carcinoma | Oncology | Dec 2028 |
| NCT06878664 | Lutetium Oxodotreotide Lu-177 | Phase 3 | Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Oncology | Jan 2029 |
| NCT05178693 | Lutetium Oxodotreotide Lu-177 | Phase 1 | Neuroendocrine Tumors | Oncology | Feb 2029 |
| NCT02754297 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Neuroendocrine Tumors | Oncology | Apr 2029 |
| NCT05773274 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Metastatic Digestive System Neuroendocrine Tumor G1 | Oncology | Apr 2029 |
| NCT06955169 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Intracranial Meningioma | Oncology | Aug 2029 |
| NCT06395402 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Neuroendocrine Tumors | Oncology | Dec 2029 |
| NCT04903899 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Neuroblastoma Recurrent | Oncology | May 2031 |
| NCT04665739 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Advanced Lung Neuroendocrine Tumor | Oncology | Sep 2032 |
| NCT04954820 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Neuroendocrine Tumors | Oncology | Oct 2033 |
| NCT04711135 | Lutetium Oxodotreotide Lu-177 | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | Oncology | Feb 2034 |
Camurus ITM Solucin Orano Med 3D Medicines (Sichuan) PharmaEssentia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.